Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- Freenome, a privately held biotech company, today announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014. This round of financing was...

Click to view original post